First Trust Nasdaq Pharmaceuticals ETF
FTXH
34 hedge funds and large institutions have $22M invested in First Trust Nasdaq Pharmaceuticals ETF in 2022 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 4 closing their positions.
225% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 4
31% more funds holding
Funds holding: 26 → 34 (+8)
29% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 7
20% more capital invested
Capital invested by funds: $18.3M → $22M (+$3.69M)
1.38% more ownership
Funds ownership: 50.72% → 52.1% (+1.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
+$2.77M |
| 2 |
SPIA
Steward Partners Investment Advisory
New York
|
+$953K |
| 3 |
CA
Cetera Advisors
Denver,
Colorado
|
+$534K |
| 4 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$477K |
| 5 |
EH
Equitable Holdings
New York
|
+$415K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$2.94M |
| 2 |
IAN
Integrated Advisors Network
Dallas,
Texas
|
-$882K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$680K |
| 4 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
-$474K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$217K |
FTXH Hedge Fund Activity: Q4 2022 in Review
34 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in First Trust Nasdaq Pharmaceuticals ETF (FTXH) for Q4 2022, worth a combined $22M — up 20% from $18.3M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new FTXH positions and 4 closed out — a net gain of 9 holders — while 9 added to existing stakes and 7 trimmed.
The largest buyer was Raymond James Financial Services Advisors, opening a new position worth an estimated $2.77M. The largest seller was Raymond James & Associates, cutting an estimated $2.94M.
- 34 institutional investors held First Trust Nasdaq Pharmaceuticals ETF (FTXH) as of Q4 2022, up from 26 in Q3 2022.
- Funds reported $22M of First Trust Nasdaq Pharmaceuticals ETF stock for Q4 2022, up 20% quarter-over-quarter.
- 13 funds opened new First Trust Nasdaq Pharmaceuticals ETF positions in Q4 2022 and 4 closed out, a net change of +9 holders.
- The largest First Trust Nasdaq Pharmaceuticals ETF buyer in Q4 2022 was Raymond James Financial Services Advisors, an estimated $2.77M added.
- The largest First Trust Nasdaq Pharmaceuticals ETF seller in Q4 2022 was Raymond James & Associates, an estimated $2.94M sold.
Based on aggregated 13F filings for Q4 2022.